Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 16/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21726717 | 1.00 | KLKB1 (0.43) | KLKB1TSHRL3MBTL1POLBGFER | |
| SCHEMBL20584317 | 0.91 | KLKB1 (0.45) | KLKB1 | |
| SCHEMBL29489461 | 0.89 | KLKB1 (0.48) | KLKB1TSHRL3MBTL1POLBGFER | |
| SCHEMBL21726632 | 0.89 | KLKB1 (0.48) | KLKB1TSHRL3MBTL1POLBGFER | |
| SCHEMBL31456851 | 0.89 | KLKB1 (0.43) | KLKB1TSHRL3MBTL1POLBGFER | |
| SCHEMBL28721208 | 0.89 | KLKB1 (0.45) | KLKB1TSHRL3MBTL1POLBGFER | |
| SCHEMBL29581256 | 0.89 | KLKB1 (0.45) | KLKB1TSHRL3MBTL1POLBGFER | |
| SCHEMBL21726705 | 0.87 | KLKB1 (0.56) | KLKB1TSHRL3MBTL1POLB | |
| SCHEMBL29581774 | 0.87 | KLKB1 (0.56) | KLKB1TSHRL3MBTL1POLB | |
| SCHEMBL20584643 | 0.86 | KLKB1 (0.44) | KLKB1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114591212-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2025-01-28 | — | — | CN | disclosed |
| EP-4019022-B1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2024-01-31 | — | — | EP | disclosed |
| US-11807605-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4019022-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220098151-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807605-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KLKB1 1/4885TSHR 3809/4885L3MBTL1 3331/4885 |
| US-20220098151-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885TSHR 3809/4885L3MBTL1 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.